Adverum Biotechnologies Net Income

Adverum Biotechnologies (ADVM) currently reports a net income of $-180M as of September 2025. That compares with $-94M in the prior-year period — down 87.8% year over year. That is below the Healthcare sector average of $17B. Use the charts on this page to explore Adverum Biotechnologies's net income history and peer comparisons.

Adverum Biotechnologies's net income decreased from $-94M to $-180M — a 87.8% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adverum Biotechnologies's net income of $-180M is lower than the Healthcare sector average of $17B. That is roughly 101.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Adverum Biotechnologies reported $-180M in net income as of September 2025. That compares with $-94M in the prior-year period — down 87.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-180M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Adverum Biotechnologies, and consider following ADVM for alerts when major investors trade the stock.